NASDAQ:TECH

Bio-Techne Shares Bounce, Investors Eye a Key Risk
····

Bio-Techne Shares Bounce, Investors Eye a Key Risk

Bio-Techne closed Wednesday at $46.70, up 2.7%, marking a three-day rebound but still 35% below its January high. Fiscal third-quarter revenue fell 2% to $311.4 million, missing Wall Street estimates as weak biotech demand and U.S. academic funding cuts weighed on sales. CEO Kim Kelderman described the academic market as “frail” and not on a clear recovery path. Bio-Techne owns 20% of Wilson Wolf and may acquire the rest.
May 21, 2026

Stock Market Today

  • 6 Key Numbers to Value Pro Medicus Ltd (ASX:PME) Shares
    May 30, 2026, 1:15 AM EDT. Pro Medicus Ltd (ASX:PME), a radiology IT software provider, has seen its share price fall 40.59% since the start of the year. The company posted $162 million in annual revenue with a 33.4% compound annual growth rate over three years. Its gross margin of 99.8% highlights operational strength. PME reported a profit of $83 million last year, growing at 39.0% CAGR over three years. Financial health is robust, with net debt of negative $153 million, indicating more cash than debt, and a low debt-to-equity ratio of 1.1%. The return on equity (ROE) stands at 50.7%, reflecting efficient capital use. These metrics provide key insights to evaluate PME's share performance this year amid market volatility.